William J. Gradishar, MD, on HER2-Negative Breast Cancer: The Treatment Pipeline

Posted: Thursday, March 21, 2019

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the top prospects in targeted therapy now under study for advanced-stage HER2-negative breast cancer, and how close they are to being used in the clinic.